Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects for whom, in the opinion of the investigator, the parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol (e.g., return for vaccination and follow-up visits).~* A male or female between, and including 6-10 weeks (42-76 days) of age at the time of the first vaccination.~* Written or oral, signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the subject. For all subjects, the consent form should be countersigned by a witness.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Born full-term (i.e., after a gestation period from 37 to 42 weeks).~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. Inhaled and topical steroids are allowed.~* Planned administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).~* Administration or planned administration of a vaccine not foreseen by the study protocol administered during the period starting from 30 days before each dose of study vaccines and ending 30 days after with the following exceptions:~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product~* Previous vaccination against diphtheria, tetanus, pertussis, H. influenzae type b and/or S. pneumoniae.~* History of, or intercurrent diphtheria, tetanus, pertussis, hepatitis B, and H. influenzae type b disease.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* Family history of congenital or hereditary immunodeficiency.~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures.~* Acute disease and/or fever at the time of enrolment.~* Fever is defined as temperature ≥ 37.5°C for oral, axillary or tympanic route, or ≥ 38.0°C on rectal route. The preferred route for recording temperature in this study will be axillary.~* Subjects with a minor illness without fever may, be enrolled at the discretion of the investigator.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (Hepatitis B immunoglobulins at birth are allowed).~* Any medical condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 76 Days
- Healthy Volunteers: t

Study Arms:
- 10Pn_4d Group (Type: EXPERIMENTAL): Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
- 10Pn Group (Type: ACTIVE_COMPARATOR): Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).